David Wotherspoon

David Wotherspoon has a diverse range of work experience in the field of biomedical research. David is currently working at Takeda as a Scientist I, where they play a crucial role in designing, generating, and testing genetically engineered cell therapies for solid tumors. David is also responsible for developing in-vitro assays and managing in-vivo model development for evaluating the efficacy of cell therapy products. Prior to this, they worked as a Research Associate Scientist at Takeda.

Before joining Takeda, David completed their PhD at Barts Cancer Institute, focusing on the role of m6A mRNA reader YTHDF2 in T cells, acute myeloid leukemia, and hematopoiesis. During their PhD, they published several research papers on their findings. David also worked as a PhD student at The University of Edinburgh and conducted research on a different project.

David's work experience also includes a research project at the University of Leeds, where they participated in an interdisciplinary project characterizing antimicrobial surgical mesh. In addition, they gained valuable experience during their time at Dstl as an Industrial Placement Student, working on canine olfaction and conducting animal behavior trials in collaboration with law enforcement and military units.

Early in their career, David had internships at ICON plc (formerly Aptiv Solutions), where they gained experience in clinical research and database management. David created a database of clinical research units and researched clinical trial regulations in different countries.

Overall, David Wotherspoon has accumulated a diverse background in biomedical research, with expertise in cell therapies, molecular biology, cancer stem cells, and clinical research.

David Wotherspoon attended Berkhamsted School from 2003 to 2012. David then enrolled at the University of Leeds, where they pursued a degree in Biological Sciences from 2012 to 2017. Subsequently, they joined Queen Mary University of London from 2018 to 2021, where they obtained their Doctor of Philosophy (PhD) in Haemato-Oncology.